Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CERES St. John's Wort mother tincture is a low-dose herbal medicinal product (phytopharmaceutical) developed by Ceres Heilmittel AG, derived from the fresh flowering tops of *Hypericum perforatum*. Unlike high-dose dry extracts, this mother tincture is prepared using a specialized pharmaceutical process that aims to preserve the plant's essential oils and complex biochemical profile. It is primarily indicated for the treatment of mild to moderate major depressive disorder, as well as associated symptoms like anxiety and restlessness. The drug's therapeutic effect is attributed to the synergistic action of its constituents, such as hypericin and hyperforin, which function as non-selective reuptake inhibitors of monoamine neurotransmitters, thereby increasing the synaptic availability of serotonin, norepinephrine, and dopamine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CERES St. John's Wort mother tincture.